Serum 25-Hydroxyvitamin D Response to Vitamin D3Supplementation 50,000 IU Monthly in Youth with HIV-1 Infection | Zendy

Peter L. Havens | Zendy; Kathleen Mulligan | Zendy; Rohan Hazra | Zendy; Patricia M. Flynn | Zendy; Brandy Rutledge | Zendy; Marta D. Van Loan | Zendy; Jorge LujánZilbermann | Zendy; Bill G. Kapogiannis | Zendy; Craig M. Wilson | Zendy; Charles B. Stephensen | Zendy; and the ALSWH Research Team | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum 25-Hydroxyvitamin D Response to Vitamin D₃Supplementation 50,000 IU Monthly in Youth with HIV-1 Infection

Author(s) -

Peter L. Havens,

Kathleen Mulligan,

Rohan Hazra,

Patricia M. Flynn,

Brandy Rutledge,

Marta D. Van Loan,

Jorge LujánZilbermann,

Bill G. Kapogiannis,

Craig M. Wilson,

Charles B. Stephensen,

and the ALSWH Research Team

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-2600

Subject(s) - efavirenz , vitamin d and neurology , placebo , medicine , vitamin d deficiency , vitamin , randomized controlled trial , dosing , cholecalciferol , gastroenterology , viral load , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , alternative medicine , pathology

Vitamin D deficiency and insufficiency occur frequently in youth with HIV infection, particularly among those receiving the antiretroviral drug efavirenz. Optimal vitamin D dosing for treatment is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research